Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2020 Oct 2;109(3):705–715. doi: 10.1002/cpt.2039

Figure 4. Bleeding outcomes following PCI by CYP2C19 metabolizer status and antiplatelet therapy.

Figure 4.

Kaplan-Meier curves for cumulative clinically significant bleeding event incidence over 12 months after PCI. Data are shown across four groups, as described in Figure 2: Clop-UM or RM, Clop-NM, Clop-IM or PM, and Alt-combined. The number of patients in each group was slightly different than for the atherothrombotic endpoint as patients were stratified based on P2Y12 therapy prescribed at the time of the bleeding event or last follow-up. The unadjusted log rank P-value for outcomes across the four groups is provided.